SIMCERE PHARMAC. GRP LTD (S2P) — Cash Flow Reinvestment Rate
SIMCERE PHARMAC. GRP LTD (S2P) has a Cash Flow Reinvestment Rate of 0.69x as of December 2025, reinvesting €1.39 Billion (capex €862.20 Million plus investments €-524.90 Million) from operating cash flow of €2.01 Billion. Check SIMCERE PHARMAC. GRP LTD (S2P) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
SIMCERE PHARMAC. GRP LTD Cash Flow Reinvestment Rate (2022–2025)
Historical reinvestment intensity for SIMCERE PHARMAC. GRP LTD across 4 annual periods. Explore SIMCERE PHARMAC. GRP LTD debt service capacity to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for SIMCERE PHARMAC. GRP LTD (2022–2025)
Year-by-year capital reinvestment analysis for SIMCERE PHARMAC. GRP LTD. For live market cap and broader valuation context, see SIMCERE PHARMAC. GRP LTD market cap and net worth.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.69x | €1.39 Billion | €2.01 Billion | €862.20 Million | ▼ -24.3% |
| 2024 | 0.91x | €1.27 Billion | €1.39 Billion | €762.57 Million | ▼ -92.6% |
| 2023 | 12.32x | €1.86 Billion | €151.05 Million | €979.86 Million | ▲ +1340.9% |
| 2022 | 0.85x | €1.16 Billion | €1.35 Billion | €678.00 Million | — |